Trade Mark Journal No.2026/008 20 February 2026
WO0000001889680 (5,42)
Office of origin: United States of America
Date of International Registration:8 September 2025
Date of designation in the UK:
8 September 2025
International priority date claimed: 8 August 2025
(United States of America)
(99327839)
- Class 5
- Pharmaceutical preparations; pharmaceutical preparations for the treatment of cystic fibrosis; pharmaceutical preparations for the treatment of genetic diseases or disorders; pharmaceutical preparations for the treatment of endocrine diseases or disorders; pharmaceutical preparations for the treatment of cellular diseases or disorders; pharmaceutical preparations for the treatment of pulmonary, respiratory, gastrointestinal, digestive, metabolic, and pancreatic diseases or disorders.
- Class 42
- Pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; testing of pharmaceuticals; consulting services for others in the field of pharmaceutical research and development; consulting services for others in the field of pharmaceuticals research; research and development in the field of cystic fibrosis; research and development in the field of genetic diseases or disorders; research and development in the field of endocrine diseases or disorders; research and development in the field of cellular diseases or disorders; research and development in the field of pulmonary, respiratory, gastrointestinal, digestive, metabolic, and pancreatic diseases or disorders.
Sionna Therapeutics, Inc.
Representative: Keith Toms, Esq. McCarter & English, LLP, 265 Franklin Street, Boston MA 02110, UNITED STATES OF AMERICA